KUKJE PHARMA (002720) Fundamentals 2026 — P/E 11.4x, Revenue Analysis | SniperIQ
KUKJE PHARMA (002720) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩70.3B, trading at ₩3320.00 on the KSC. This SniperIQ fundamentals page covers KUKJE PHARMA's valuation (P/E 11.4x, P/B 0.7x), profitability (net margin 3.4%), revenue (₩175.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is KUKJE PHARMA's market cap?
KUKJE PHARMA (002720) has a market capitalization of approximately ₩70.3B, trading at ₩3320.00 on the KSC. Market cap moves with the live share price.
What is KUKJE PHARMA's P/E ratio?
KUKJE PHARMA's trailing twelve-month P/E ratio is 11.4x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is KUKJE PHARMA?
KUKJE PHARMA runs a net profit margin of 3.4%, a gross margin of 53.3%, and an operating margin of 3.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does KUKJE PHARMA generate?
KUKJE PHARMA reported revenue of ₩175.5B for fiscal year 2025, with net income of ₩5.7B and earnings per share (EPS) of 279.51. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does KUKJE PHARMA pay a dividend?
KUKJE PHARMA offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is KUKJE PHARMA financially healthy?
KUKJE PHARMA carries a debt-to-equity ratio of 0.31x and a current ratio of 1.09x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is KUKJE PHARMA a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For KUKJE PHARMA (002720) the key facts are: market cap ₩70.3B, P/E 11.4x, revenue ₩175.5B, 52-week range 3115-5470. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track KUKJE PHARMA's full fundamentals live
Get KUKJE PHARMA's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.